Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)

Clinical trial NCT05037279 · RECRUITING

Trial details

NCT number: NCT05037279
Sponsor: Verity Pharmaceuticals Inc.
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Bladder Cancer Bladder Cancer Recurrent Neoplasm Recurrence Urothelial Carcinoma Bladder Urothelial Carcinoma Recurrent Non-Invasive Bladder Urothelial Carcinoma

Start date: 2024-04-24
Primary completion: 2029-02-01
Enrollment: 540

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.